Daily News: August 13, 2014

Oxford Finance, Square 1 Provide Facility to Tarsa

Tarsa Therapeutics announced it has secured a $10 million senior credit facility from Oxford Finance and Square 1 Bank. The company intends to use the proceeds to support its plans to file a new drug application with the U.S. Food and Drug Administration (FDA) for its Ostora tablet for the treatment of postmenopausal osteoporosis, currently targeted for early 2015.

Tarsa is developing Ostora, a novel oral formulation of calcitonin for the treatment of postmenopausal osteoporosis in women greater than five years post menopause, when alternative treatments are not available.